Preclinical-stage biotechnology company developing in vivo cell and gene therapies using modular immune receptors and purpose-built delivery vectors
Preclinical-stage biotechnology company developing in vivo cell and gene therapies using modular immune receptors and purpose-built delivery vectors. Its MARC platform separates immune-cell targeting from signaling, while its MoVe platform enables targeted delivery and engineering of immune and other cells. Initial applications include CAR-T therapies for solid tumors, with potential expansion into autoimmune, inflammatory, neurological, and regenerative medicine indications.